Every once in a while, a company comes along that doesn’t just push boundaries, it erases them entirely. LambdaVision is that company. Born from the labs at the University of Connecticut under Dr. Robert R. Birge and driven by the relentless vision of Dr. Nicole L. Wagner, this biotech upstart is building the first protein-based artificial retina… in space. Not a metaphor, aboard the ISS, where gravity doesn’t get to mess with perfection. When most companies chase scale, LambdaVision chases the stratosphere.
The company just closed a $7M seed round co-led by Seven Seven Six and Aurelia Foundry Fund, with support from Seraphim Space. This round extends their runway into 2027 and anchors a new chapter in space-enabled biomanufacturing. Seven Seven Six, founded by Reddit’s Alexis Ohanian and led by Katelin Holloway, backs founders who rewrite what’s possible. Aurelia Foundry Fund, co-led by MIT’s Dr. Ariel Ekblaw, invests in deep tech that uses space to transform life on Earth. Add Rob Desborough and Seraphim Space, the global heavyweight in SpaceTech, and you’ve got a syndicate that doesn’t just invest in innovation, it manufactures it.
LambdaVision’s story reads like a sci-fi origin with Ivy League precision. Dr. Birge spent 40+ years studying bacteriorhodopsin, a light-activated protein from salt marsh microbes tough enough to survive extremes that would vaporize most life. Dr. Wagner took that science and turned it into salvation for millions losing their sight to retinitis pigmentosa and age-related macular degeneration. It’s a 200-layer film of protein thin as light, built molecule by molecule in microgravity to mimic the natural retina and send signals straight to the brain.
Nine successful ISS missions. Over $12M in NASA backing. A validated manufacturing process proving that microgravity isn’t just a scientific curiosity, it’s a production advantage. Partnering with Space Tango, LambdaVision has fine-tuned a process that delivers flawless uniformity and stability no Earth-bound lab can match. That’s not hype, it’s physics. This $7M round fuels IND-enabling efficacy and toxicity studies, scales space-manufactured batches, and drives preclinical work toward human trials. LambdaVision isn’t chasing trends, it’s defining an entirely new category at the intersection of biotech, medtech, and orbital manufacturing.
Dr. Nicole L. Wagner, Dr. Robert R. Birge, and Dr. Jordan A. Greco aren’t just restoring sight, they’re proving what vision really looks like. LambdaVision isn’t just seeing the future; it’s building it, layer by layer, 250 miles above the Earth.
